Multidrug transporters as drug targets.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Current Drug Targets

• Publication date

  2006-07-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/138945006778019264PMID 16918320
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protection of platinum–DNA adduct formation and reversal of cisplatin resistance by anti‐MRP2 hammerhead ribozymes in human cancer cells

  2005cited by this paper
• Inhibitors of p-glycoprotein--lead identification and optimisation.

  2005cited by this paper
• Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract

  2004cited by this paper
• Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies

  2004cited by this paper
• Presence of anionic phospholipids rules the membrane localization of phenothiazine type multidrug resistance modulator.

  2004cited by this paper
• P-Glycoprotein-based drug-drug interactions: preclinical methods and relevance to clinical observations

  2004cited by this paper
• Targeting an extracellular epitope of the human multidrug resistance protein 1 (MRP1) in malignant cells with a novel recombinant single chain Fv antibody

  2004cited by this paper
• Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.

  2003cited by this paper
• Strategies for reversing drug resistance

  2003cited by this paper
• P‐glycoprotein‐mediated intestinal and biliary digoxin transport in humans

  2003cited by this paper
• Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin.

  2003cited by this paper
• Lipids as a target for drugs modulating multidrug resistance of cancer cells.

  2003cited by this paper
• Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines.

  2003cited by this paper
• Inhibition of P-Glycoprotein by Newer Antidepressants

  2003cited by this paper
• The Farnesyl Protein Transferase Inhibitor Lonafarnib (SCH66336) Is an Inhibitor of Multidrug Resistance Proteins 1 and 2

  2003cited by this paper
• Multidrug resistance in cancer: role of ATP–dependent transporters

  2002cited by this paper
• Inhibition of the multidrug resistance protein 1 (MRP1) by peptidomimetic glutathione-conjugate analogs.

  2002cited by this paper
• Role of the N-terminal Transmembrane Region of the Multidrug Resistance Protein MRP2 in Routing to the Apical Membrane in MDCKII Cells*

  2002cited by this paper
• St Johns wort increases expression of P-glycoprotein: implications for drug interactions.

  2002cited by this paper
• Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity.

  2001cited by this paper
• The Structure of the Multidrug Resistance Protein 1 (MRP1/ABCC1)

  2001cited by this paper
• Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.

  2001cited by this paper
• Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport.

  2001cited by this paper
• Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics, and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation.

  2001cited by this paper
• Mice Lacking the Multidrug Resistance Protein 1 Are Resistant to Streptococcus pneumoniae-Induced Pneumonia1

  2001cited by this paper
• Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol a on MRP1 function

  2001cited by this paper
• Multiple physiological functions for multidrug transporter P-glycoprotein?

  2000cited by this paper
• Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance

  2000cited by this paper
• Induction of P‐glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction

  2000cited by this paper
• Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation.

  2000cited by this paper
• The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes.

  2000cited by this paper
• A family of drug transporters: the multidrug resistance-associated proteins.

  2000cited by this paper
• Characterization of the amino-terminal regions in the human multidrug resistance protein (MRP1).

  2000cited by this paper
• Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier.

  2000cited by this paper
• The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance.

  2000cited by this paper
• Endothelin B receptor-mediated regulation of ATP-driven drug secretion in renal proximal tubule.

  2000cited by this paper
• Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P‐glycoprotein

  2000cited by this paper
• Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P.

  2000cited by this paper
• St John's Wort induces intestinal P‐glycoprotein/MDR1 and intestinal and hepatic CYP3A4

  2000cited by this paper
• Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export

  2000cited by this paper
• Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells.

  1999cited by this paper
• Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833.

  1999cited by this paper
• The Contribution of P‐glycoprotein to Pharmacokinetic Drug‐Drug Interactions

  1999cited by this paper
• P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.

  1999cited by this paper
• Mechanisms and interaction of vinblastine and reduced glutathione transport in membrane vesicles by the rabbit multidrug resistance protein Mrp2 expressed in insect cells.

  1999cited by this paper
• A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier.

  1999cited by this paper
• Biochemical, cellular, and pharmacological aspects of the multidrug transporter.

  1999cited by this paper
• Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2)

  1999cited by this paper
• Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier.

  1999cited by this paper
• Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione.

  1999cited by this paper
• Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments].

  1999cited by this paper
• Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo.

  1999cited by this paper
• Active lucifer yellow secretion in renal proximal tubule: evidence for organic anion transport system crossover.

  1999cited by this paper
• Glutathione metabolism and glutathione S‐conjugate export ATPase (MRP1/GS‐X pump) activity in cancer

  1998cited by this paper
• Cyclic AMP stimulates sorting of the canalicular organic anion transporter (Mrp2/cMoat) to the apical domain in hepatocyte couplets.

  1998cited by this paper
• Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione.

  1998cited by this paper
• Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome.

  1998cited by this paper
• The selection of intracellular antibodies.

  1998cited by this paper
• Multidrug Resistance Protein 1 Protects the Oropharyngeal Mucosal Layer and the Testicular Tubules against Drug-induced Damage

  1998cited by this paper
• ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene.

  1997cited by this paper
• Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein

  1997cited by this paper
• Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi.

  1997cited by this paper
• Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione.

  1997cited by this paper
• A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells.

  1997cited by this paper
• ATPase Activity of Purified Multidrug Resistance-associated Protein*

  1997cited by this paper
• Functional analysis of the nucleotide binding domains of the multidrug resistance protein (MRP).

  1997cited by this paper
• The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis.

  1997cited by this paper
• A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin‐Johnson syndrome

  1997cited by this paper
• Membrane Topology and Glycosylation of the Human Multidrug Resistance-associated Protein (*)

  1996cited by this paper
• Transporting therapeutics across the blood-brain barrier.

  1996cited by this paper
• cDNA Cloning of the Hepatocyte Canalicular Isoform of the Multidrug Resistance Protein, cMrp, Reveals a Novel Conjugate Export Pump Deficient in Hyperbilirubinemic Mutant Rats*

  1996cited by this paper
• Multidrug Resistance Protein (MRP)-mediated Transport of Leukotriene C and Chemotherapeutic Agents in Membrane Vesicles

  1996cited by this paper
• Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells.

  1996cited by this paper
• ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump.

  1996cited by this paper
• Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells.

  1996cited by this paper
• Effect of combination of suboptimal concentrations of P‐glycoprotein blockers on the proliferation of MDR1 gene expressing cells

  1996cited by this paper
• ATP-dependent 17 beta-estradiol 17-(beta-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids.

  1996cited by this paper
• Tissue distribution of the multidrug resistance protein.

  1996cited by this paper
• Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump.

  1996cited by this paper
• Structure and in vitro substrate specificity of the murine multidrug resistance-associated protein.

  1996cited by this paper
• Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides.

  1996cited by this paper
• A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation.

  1996cited by this paper
• Congenital Jaundice in Rats with a Mutation in a Multidrug Resistance-Associated Protein Gene

  1996cited by this paper
• High level expression of the multidrug resistance (MDR1) gene in the normal bladder urothelium: a potential involvement in protection against carcinogens?

  1996cited by this paper
• Phosphorylation of the multidrug resistance associated protein gene encoded protein P190.

  1995cited by this paper
• Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.

  1995cited by this paper
• Characterization of the M(r) 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cell.

  1995cited by this paper
• Evaluation of the Combination of Vinblastine and Quinidine in Patients with Metastatic Renal Cell Carcinoma: A Phase I Study

  1995cited by this paper
• Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor.

  1995cited by this paper
• Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein.

  1995cited by this paper
• Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL.

  1994cited by this paper
• Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport.

  1994cited by this paper
• P-glycoprotein expression and function in circulating blood cells from normal volunteers.

  1994cited by this paper
• Biochemistry of multidrug resistance mediated by the multidrug transporter.

  1993cited by this paper
• Clinical trials of agents that reverse multidrug resistance. A literature review

  1993cited by this paper
• Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines.

  1993cited by this paper
• Multidrug resistance-associated protein: sequence correction.

  1993cited by this paper
• Increased accumulation of drugs in a multidrug resistant cell line by alteration of membrane biophysical properties.

  1993cited by this paper
• Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.

  1993cited by this paper
• Reversal of multidrug resistance by surfactants.

  1992cited by this paper

• Study of fingolimod, nitric oxide inhibitor, and P-glycoprotein inhibitor in modulating the P-glycoprotein expression via an endothelin–sphingolipid pathway in an animal model of pharmacoresistant epilepsy

  2023cites this paper
• A Plasmodium falciparum ATP-binding cassette transporter is essential for liver stage entry into schizogony

  2022cites this paper
• In Vitro Photodynamic Treatment Modality for A375 Melanoma Cell Line Using a Sulphonated Aluminum Phthalocyanine Chloride-Photosensitizer-Gold Nanoparticle Conjugate

  2022cites this paper
• Cigarette smoke extract combined with LPS down-regulates the expression of MRP2 in chronic pulmonary inflammation may be related to FXR.

  2021cites this paper
• Combined moxidectin-levamisole treatment against multidrug-resistant gastrointestinal nematodes: A four-year efficacy monitoring in lambs.

  2021cites this paper
• Saikosaponin-d Inhibits the Hepatoma Cells and Enhances Chemosensitivity Through SENP5-Dependent Inhibition of Gli1 SUMOylation Under Hypoxia

  2019cites this paper
• Role of ABC Transporters in Veterinary Medicine: Pharmaco- Toxicological Implications.

  2019cites this paper
• Acute pain alters P-glycoprotein-containing protein complexes in rat cerebral microvessels: Implications for P-glycoprotein trafficking

  2018cites this paper
• Chronic morphine exposure potentiates p-glycoprotein trafficking from nuclear reservoirs in cortical rat brain microvessels

  2018cites this paper
• The Sphingosine 1‐Phosphate Analogue FTY720 Alleviates Seizure‐induced Overexpression of P‐Glycoprotein in Rat Hippocampus

  2018cites this paper
• Screening of novel RGD peptides to modify nanoparticles for targeted cancer therapy.

  2017cites this paper
• The opioid epidemic: a central role for the blood brain barrier in opioid analgesia and abuse

  2017cites this paper
• P-glycoprotein traffics from the nucleus to the plasma membrane in rat brain endothelium during inflammatory pain

  2016cites this paper
• Identification of P‐glycoprotein co‐fractionating proteins and specific binding partners in rat brain microvessels

  2015cites this paper
• Signaling pathways that regulate basal ABC transporter activity at the blood- brain barrier.

  2014cites this paper
• ABC transporter regulation by signaling at the blood-brain barrier: relevance to pharmacology.

  2014cites this paper
• Glycyrrhizic Acid in the Treatment of Liver Diseases: Literature Review

  2014influential citation
• Inhibition or Knockdown of ABC Transporters Enhances Susceptibility of Adult and Juvenile Schistosomes to Praziquantel

  2014cites this paper
• Schistosome ABC multidrug transporters: From pharmacology to physiology

  2014cites this paper
• The Blood Brain Barrier (BBB)

  2014cites this paper
• ABC multidrug transporters in schistosomes and other parasitic flatworms.

  2013cites this paper
• ABC Transporters at the Blood–Brain Barrier

  2013cites this paper
• Pharmacology and potential physiological significance of schistosome multidrug resistance transporters.

  2012cites this paper
• Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain

  2012cites this paper
• Macrocyclic lactones and cellular transport-related drug interactions: a perspective from in vitro assays to nematode control in the field.

  2012cites this paper
• Potential therapy of multidrug-resistant and extremely drug-resistant tuberculosis with thioridazine.

  2012cites this paper
• Effects of glycyrrhizin on biliary transport and hepatic levels of glutathione in rats

  2012cites this paper
• Oral Delivery of Macromolecules for the Development of Therapeutic Agents

  2011cites this paper
• Synthetic surfactant food additives can cause intestinal barrier dysfunction.

  2011cites this paper
• Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells.

  2010cites this paper
• The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel

  2010cites this paper
• Drug interactions medicine

  2010cites this paper
• Multidrug Resistance Mediated by Half ABC Transporter ABCG2*: Multidrug Resistance Mediated by Half ABC Transporter ABCG2*

  2010cites this paper
• Bacterial Multidrug Transporters: Molecular and Clinical Aspects

  2009cites this paper
• Role of Membrane Transporters, P-Glycoprotein and Mrp1, in The Placental Transfer of Drugs With Special Reference to Saquinavir and Quetiapine

  2009cites this paper
• Disruption of a Plasmodium falciparum Multidrug Resistance-associated Protein (PfMRP) Alters Its Fitness and Transport of Antimalarial Drugs and Glutathione

  2009cites this paper
• NanoART, neuroAIDS and CNS drug delivery.

  2009cites this paper
• P-glycoprotein activity in renal clear cell carcinoma.

  2009cites this paper
• Algal chemical ecology

  2008cites this paper
• [Factors to consider in managing drug interactions in clinical practice].

  2008cites this paper
• Anchoring Junctions As Drug Targets: Role in Contraceptive Development

  2008cites this paper
• Assessment of golgi apparatus versus plasma membrane-localized multi-drug resistance-associated protein 1.

  2008cites this paper
• ヒスタミンH1受容体遮断薬Ebastineと血液脳関門のP糖タンパク（P-gp）阻害薬であるVerapamilとの併用による薬物相互作用に関する臨床薬理試験

  2008cites this paper
• Facteurs à prendre en considération pour la gestion des interactions médicamenteuses en pratique clinique

  2008cites this paper
• Herbivore Offense in the Sea: The Detoxifi cation and Transport of Secondary Metabolites

  2008cites this paper
• Adult human sarcomas. II. Medical oncology

  2007cites this paper
• Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects.

  2007cites this paper
• Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) I. Preclinical aspects.

  2007cites this paper
• Imaging multidrug resistance with 4-[18F]fluoropaclitaxel.

  2007cites this paper
• Waltzing transporters and 'the dance macabre' between humans and bacteria

  2007cites this paper
• Multidrug Effl ux Pumps: Structure, Mechanism, and Inhibition

  2007cites this paper
• Biomarkers, Laboratory, and Animal Models for the Design and Development of Adjunctive Therapies for HIV-1 Dementia and other Neuroinflammatory Disorders

  2007cites this paper
• Protective effects of hepatocellular canalicular conjugate export pump (Mrp2) on sodium arsenite-induced hepatic dysfunction in rats.

  2007cites this paper
• Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy

  2007cites this paper
• ABC transporters, neural stem cells and neurogenesis – a different perspective

  2006cites this paper